DexCom (NASDAQ:DXCM) Price Target Raised to $90.00

DexCom (NASDAQ:DXCM) had its price objective increased by stock analysts at Mizuho from $78.00 to $90.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has an “outperform” rating on the medical device company’s stock. Mizuho’s price objective points to a potential upside of 38.29% from the company’s current price.

DXCM has been the topic of a number of other reports. JPMorgan Chase & Co. dropped their price objective on DexCom from $90.00 to $75.00 and set a “neutral” rating on the stock in a research note on Friday, October 31st. Weiss Ratings raised DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, February 4th. Wells Fargo & Company set a $93.00 price target on DexCom and gave the stock an “overweight” rating in a report on Friday, October 31st. Barclays restated an “underweight” rating and issued a $72.00 price objective on shares of DexCom in a research note on Friday. Finally, Robert W. Baird set a $82.00 target price on shares of DexCom in a research note on Friday, October 31st. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $85.59.

DexCom Trading Down 4.5%

NASDAQ:DXCM opened at $65.08 on Friday. DexCom has a 12 month low of $54.11 and a 12 month high of $93.25. The firm has a market cap of $25.38 billion, a price-to-earnings ratio of 36.16, a P/E/G ratio of 1.22 and a beta of 1.49. The company has a quick ratio of 1.38, a current ratio of 1.56 and a debt-to-equity ratio of 0.45. The company’s 50 day moving average is $68.94 and its 200-day moving average is $69.88.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.03. The business had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.25 billion. DexCom had a net margin of 15.96% and a return on equity of 30.65%. DexCom’s quarterly revenue was up 13.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.45 EPS. Equities analysts anticipate that DexCom will post 2.03 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jennison Associates LLC increased its stake in shares of DexCom by 9.4% during the 2nd quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock worth $1,005,367,000 after purchasing an additional 994,300 shares during the last quarter. Marshall Wace LLP grew its holdings in DexCom by 260.7% during the second quarter. Marshall Wace LLP now owns 3,822,085 shares of the medical device company’s stock worth $333,630,000 after purchasing an additional 2,762,504 shares during the period. E. Ohman J or Asset Management AB grew its holdings in DexCom by 400.2% during the third quarter. E. Ohman J or Asset Management AB now owns 77,492 shares of the medical device company’s stock worth $5,214,000 after purchasing an additional 62,000 shares during the period. Zevenbergen Capital Investments LLC grew its holdings in DexCom by 10.0% during the third quarter. Zevenbergen Capital Investments LLC now owns 685,433 shares of the medical device company’s stock worth $46,123,000 after purchasing an additional 62,098 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in DexCom by 11.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 212,045 shares of the medical device company’s stock worth $14,269,000 after buying an additional 21,352 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

Key Headlines Impacting DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Q4 results beat consensus: DXCM reported $0.68 EPS vs. $0.65 expected and revenue of $1.26B (up ~13% YoY), showing continued top-line growth and margin improvement that likely drove buyer interest. Dexcom beats quarterly estimates on strong demand for glucose monitors
• Positive Sentiment: Company press release and investor materials provide supporting detail and guidance context — investors had concrete slides and call access to validate the beat. Dexcom Reports Fourth Quarter and Fiscal Year 2025 Financial Results
• Positive Sentiment: Management commentary/transcripts emphasize robust demand and product momentum (useful for gauging sustainability of growth). DexCom (DXCM) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Analysts remain generally bullish — coverage pieces on target prices keep upside expectations in the market narrative, but targets vary and will influence trading as updates arrive. What Are Wall Street Analysts’ Target Price for DexCom Stock?
• Neutral Sentiment: New product/engagement initiative: a Stelo AI upgrade aims to deepen consumer metabolic-health engagement — potentially expands TAM and recurring revenue if adoption follows. DexCom Stelo AI Upgrade Aims To Deepen Consumer Metabolic Health Engagement
• Neutral Sentiment: Press and transcript coverage (Seeking Alpha, Zacks, Benzinga, SFGATE) provide overlapping recaps — useful for detail but largely reiterate the beat rather than new catalysts. DexCom: Q4 Earnings Snapshot
• Negative Sentiment: Technical/valuation headwinds: DXCM trades below its 50- and 200-day moving averages and carries a relatively high PE (~36x), which could limit near-term upside despite the beat. (Background market data: market cap ~$25.4B, P/E-G ~1.22.)
• Negative Sentiment: Short-interest reporting appears inconsistent (entries showing 0 shares), suggesting noisy/uncertain data on positioning — could add volatility if corrected or if short activity actually rises.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.